Immunome (NASDAQ:IMNM) Given Overweight Rating at Stephens

Stephens reiterated their overweight rating on shares of Immunome (NASDAQ:IMNM) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

A number of other brokerages have also issued reports on IMNM. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday, March 10th. Guggenheim decreased their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday. Finally, Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome currently has a consensus rating of “Buy” and a consensus target price of $25.50.

Immunome Trading Up 1.1 %

NASDAQ:IMNM opened at $8.66 on Thursday. The firm has a market capitalization of $690.87 million, a PE ratio of -1.07 and a beta of 1.93. The stock has a 50 day moving average of $9.80 and a 200-day moving average of $11.62. Immunome has a 52 week low of $8.30 and a 52 week high of $26.70.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. As a group, analysts predict that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome during the 4th quarter valued at $75,000. AlphaQuest LLC lifted its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after acquiring an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after acquiring an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter valued at $95,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.